Clinical study on liposomal amphotericin B (Ambisome) in deep fungal infections in China.

Abstract

Ambisome (L-Amb) was used to treat nine cases of meningitis or menigoencephalitis by Cryptococcus neoformans and 28 cases of other deep fungal infections. A retrospective study on conventional amphotericin B (C-Amb) was performed as the control. A series of indices was observed including curative effect, fungal clearance rate, course of treatment, daily dose, cumulative dose and adverse effects. Nine cases of cryptococcal meningitis or menigoencephalitis treated with Ambisome were clinically cured with an effective rate of 100%, within a mean course of 50 days, which was shorter than that of C-Amb, by a mean cumulative dose of 1807.2 mg, which was not statistically significant in comparison with C-Amb. Fungal clearance rate on the second month of treatment was 89% with Ambisome, which was higher than that of C-Amb. Twenty-eight cases of other deep fungal infections treated with Ambisome were clinically cured with an effective rate of 92%, within a mean course of 19.3 days, by a mean cumulative dose of 907.5 mg, and fungal clearance rate on the second and third month was 75 and 92%, respectively. The adverse effects by Ambisome decreased evidently compared with those by C-Amb.

• Authors: H Wei, W Hai, L Wanqing
• Journal: Mycoses (Mycoses) Vol. 46 Issue 1-2 Pg. 24-8 (Feb 2003) ISSN: 0933-7407 [Print] Germany
• PMID: 12588479 (Publication Type: Journal Article)

Chemical References

• Antifungal Agents
• Liposomes
• liposomal amphotericin B
• Amphotericin B

Topics

• Adolescent
• Adult
• Amphotericin B (administration & dosage, adverse effects, therapeutic use)
• Antifungal Agents (administration & dosage, adverse effects, therapeutic use)
• Child
• Child, Preschool
• China
• Cryptococcosis (drug therapy)
• Cryptococcus neoformans (drug effects, growth & development)
• Drug Delivery Systems
• Female
• Humans
• Liposomes
• Male
• Meningitis, Cryptococcal (complications, drug therapy)
• Middle Aged
• Treatment Outcome